Arcus Biosciences Inc

RCUS

Company Profile

  • Business description

    Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

  • Contact

    3928 Point Eden Way
    HaywardCA94545
    USA

    T: +1 510 694-6200

    E: [email protected]

    https://www.arcusbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    674

Stocks News & Analysis

stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.
stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,934.3045.10-0.50%
CAC 407,834.5816.300.21%
DAX 4024,217.5078.43-0.32%
Dow JONES (US)44,749.2055.290.12%
FTSE 1009,120.3118.06-0.20%
HKSE25,388.35278.83-1.09%
NASDAQ21,118.8560.890.29%
Nikkei 22541,456.23370.11-0.88%
NZX 50 Index12,853.4648.330.38%
S&P 5006,379.7016.350.26%
S&P/ASX 2008,666.9042.50-0.49%
SSE Composite Index3,593.6612.07-0.33%

Market Movers